nach oben

Erschienen in:

10.10.2019 | Review

Ocular abnormalities in beta thalassemia patients: prevalence, impact, and management strategies

verfasst von: Samira Heydarian, Reza Jafari, Kiumars Nowroozpoor Dailami, Hassan Hashemi, Ebrahim Jafarzadehpour, Mohsen Heirani, Abbasali Yekta, Monireh Mahjoob, Mehdi Khabazkhoob

Erschienen in: International Ophthalmology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Beta thalassemia (β-thalassemia) is a hereditary disease caused by defective globin synthesis and can be classified into three categories of minor (β-TMi), intermedia (β-TI), and major (β-TM) thalassemia. The aim of our study is to investigate the effects of β-thalassemia and its treatment methods on different parts of the eye and how early-diagnostic methods of ocular complications in this disorder would prevent further ocular complications in these patients by immediate treatment and diet change.

Methods

We developed a search strategy using a combination of the words Beta thalassemia, Ocular abnormalities, Iron overload, chelation therapy to identify all articles from PubMed, Web of Science, Scopus, and Google Scholar up to December 2018. To find more articles and to ensure that databases were thoroughly searched, the reference lists of selected articles were also reviewed.

Results

Complications such as retinopathy, crystalline lens opacification, color vision deficiency, nyctalopia, depressed visual field, reduced visual acuity, reduced contrast sensitivity, amplitude reduction in a-wave and b-wave in Electroretinography (ERG), and decrease in the Arden ratio in Electrooculography (EOG) have all been reported in β-thalassemia patients undergoing chelation therapy.

Conclusion

Ocular problems due to β-thalassemia may be a result of anemia, iron overload in the body tissue, side effects of iron chelators, and the complications of orbital bone marrow expansion.

Provan D, Singer CR, Baglin T, Dokal I (2009) Oxford handbook of clinical haematology. Oxford University Press, Oxford

Cao A, Galanello R (2010) Beta-thalassemia. Genet Med 12(2):61PubMed

Olivieri NF, Nathan DG, MacMillan JH et al (1994) Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 331(9):574–578PubMed

He X, Hahn P, Iacovelli J et al (2007) Iron homeostasis and toxicity in retinal degeneration. Prog Retin Eye Res 26(6):649–673PubMedPubMedCentral

Brittenham GM, Griffith PM, Nienhuis AW et al (1994) Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 331(9):567–573PubMed

Bollig C, Schell LK, Rücker G et al (2017) Deferasirox for managing iron overload in people with thalassaemia. Cochrane Database Syst Rev 8:CD007476

Olivieri NF, Brittenham GM, Matsui D et al (1995) Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 332(14):918–922PubMed

Liaska A, Petrou P, Georgakopoulos CD et al (2016) β-Thalassemia and ocular implications: a systematic review. BMC Ophthalmol 16(1):102PubMedPubMedCentral

Gartaganis S, Ismiridis K, Papageorgiou O, Beratis NG, Papanastasiou D (1989) Ocular abnormalities in patients with β-thalassemia. Am J Ophthalmol 108(6):699–703PubMed

10.

Gaba A, D’Souza P, Chandra J, Narayan S, Sen S (1998) Ocular changes in β-thalassemia. Ann Ophthalmol Glaucoma 30(6):357–360

11.

Shahriari H, Ghasemzadeh F, Eshghi P, Masoomian B (2006) Ocular side effects of desferal in patients with β-thalassemia. Bina J Ophthalmol 11:519–523

12.

Taher A, Bashshur Z, Shamseddeen WA et al (2006) Ocular findings among thalassemia patients. Am J Ophthalmol 142(4):704–705PubMed

13.

Rahiminejad M, Rahiminejad S, Rahimi M et al (2009) Ocular complication and visual evoked potential in β-thalassemia patients on desferal therapy. Res J Biol Sci 4(8):928–932

14.

Taneja R, Malik P, Sharma M, Agarwal MC (2010) Multiple transfused thalassemia major: ocular manifestations in a hospital-based population. Indian J Ophthalmol 58(2):125PubMedPubMedCentral

15.

Dewan P, Gomber S, Chawla H, Rohatgi J (2011) Ocular changes in multi-transfused children with β-thalassaemia receiving desferrioxamine: a case-control study. S Afr J Child Health 5(1):11–14

16.

Nowroozzadeh MH, Kalantari Z, Namvar K, Meshkibaf MH (2011) Ocular refractive and biometric characteristics in patients with thalassaemia major. Clin Exp Optom 94(4):361–366PubMed

17.

Jafari R, Heydarian S, Karami H et al (2015) Ocular abnormalities in multi-transfused beta-thalassemia patients. Indian J Ophthalmol 63(9):710PubMedPubMedCentral

18.

Kumble D, Sekhon PK (2017) Ocular involvement in beta thalassemia major: a prospective study in an Indian cohort. Int J Contemp Pediatr 4(3):780–782

19.

Merchant RH, Punde H, Thacker N, Bhatt D (2017) Ophthalmic evaluation in beta-thalassemia. Indian J Pediatr 84(7):509–514PubMed

20.

Barteselli G, Dell’arti L, Finger RP et al (2014) The spectrum of ocular alterations in patients with beta-thalassemia syndromes suggests a pathology similar to pseudoxanthoma elasticum. Ophthalmology 121:709–718PubMed

21.

Saif AT, Saif PS, Dabous O (2017) Fundus changes in thalassemia in Egyptian patients. Delta J Ophthalmol 18(1):20

22.

Voskaridou E, Terpos E (2004) New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 127(2):127–139PubMed

23.

Jensen C, Tuck S, Agnew J et al (1998) High prevalence of low bone mass in thalassaemia major. Br J Haematol 103(4):911–915PubMed

24.

Weatherall DJ, Clegg JB (2008) The thalassaemia syndromes. Wiley, Hoboken

25.

Heydarian S, Jafari R, Karami H (2016) Refractive errors and ocular biometry components in thalassemia major patients. Int Ophthalmol 36(2):267–271PubMed

26.

Parentin F, Tonini G, Perissutti P (2004) Refractive evaluation in children with growth defect. Curr Eye Res 28(1):11–15PubMed

27.

Parentin F, Perissutti P (2005) Congenital growth hormone deficiency and eye refraction: a longitudinal study. Ophthalmologica 219(4):226–231PubMed

28.

Bourla DH, Laron Z, Snir M, Lilos P, Weinberger D, Axer-Siegel R (1197) Insulinlike growth factor I affects ocular development: a study of untreated and treated patients with Laron syndrome. Ophthalmology 113(7):e1–e5

29.

Khalaj M, Mahyar A, Jahan Hashemi H, Godsi F (2009) Assessing the refractive errors in beta-thalassemia major patients. J Guilan Univ Med Sci 17(68):42–49

30.

Elkitkat RS, El-Shazly AA, Ebeid WM, Deghedy MR (2018) Relation of anthropometric measurements to ocular biometric changes and refractive error in children with thalassemia. Eur J Ophthalmol 28(2):139–143PubMed

31.

Gartaganis S, Georgakopoulos C, Exarchou A et al (2003) Alterations in conjunctival cytology and tear film dysfunction in patients with β-thalassemia. Cornea 22(7):591–597PubMed

32.

Arcasoy A, Cavdar AO (1975) Changes of trace minerals (serum iron, zinc, copper and magnesium) in thalassemia. Acta Haematol 53(6):341–346PubMed

33.

De Luca C, Filosa A, Grandinetti M, Maggio F, Lamba M, Passi S (1999) Blood antioxidant status and urinary levels of catecholamine metabolites in β-thalassemia. Free Radic Res 30(6):453–462PubMed

34.

Borgna-Pignatti C, Cammareri V, De Stefano P, Magrini U (1984) The sicca syndrome in thalassaemia major. Br Med J (Clin Res Ed) 288(6418):668–669

35.

Popescu C, Siganos D, Zanakis E, Padakis A (1998) The mechanism of cataract formation in persons with beta-thalassemia. Oftalmologia (Bucharest, Romania: 1990) 45(4):10–13

36.

Athanasiadis I, Konstantinidis A, Kyprianou I, Robinson R, Moschou V, Kouzi-Koliakos K (2007) Rapidly progressing bilateral cataracts in a patient with beta thalassemia and pellagra. J Cataract Refract Surg 33(9):1659–1661PubMed

37.

Dhawan V, KhR K, Marwaha R, Ganguly NK (2005) Antioxidant status in children with homozygous thalassemia. Indian Pediatr 42(11):1141–1145PubMed

38.

Marsili S, Salganik RI, Albright CD et al (2004) Cataract formation in a strain of rats selected for high oxidative stress. Exp Eye Res 79(5):595–612PubMed

39.

Mehdizadeh M, Nowroozzadeh MH (2009) Posterior subcapsular opacity in two patients with thalassaemia major following deferiprone consumption. Clin Exp Optom 92(4):392–394PubMed

40.

Aksoy A, Aslan L, Aslankurt M et al (2014) Retinal fiber layer thickness in children with thalassemia major and iron deficiency anemia. Semin ophthalmol 29(1):22–26PubMed

41.

Bhoiwala DL, Dunaief JL (2016) Retinal abnormalities in β-thalassemia major. Surv Ophthalmol 61(1):33–50PubMed

42.

Genead MA, Fishman GA, Anastasakis A, Lindeman M (2010) Macular vitelliform lesion in desferrioxamine-related retinopathy. Doc Ophthalmol 121:161–166PubMedPubMedCentral

43.

Georgakopoulos CD, Tsapardoni F, Kostopoulou EV, Makri OE (2018) Pattern dystrophies in patients treated with deferoxamine: report of two cases and review of the literature. BMC Ophthalmol 18(1):246PubMedPubMedCentral

44.

Gonzales CR, Lin AP, Engstrom RE, Kreiger AE (2004) Bilateral vitelliform maculopathy and deferoxamine toxicity. Retina (Philadelphia, Pa) 24(3):464–467

45.

Viola F, Barteselli G, Dell’Arti L et al (2014) Multimodal imaging in deferoxamine retinopathy. Retina (Philadelphia, Pa) 34(7):1428–1438

46.

Finger RP, Issa PC, Ladewig MS et al (2009) Pseudoxanthoma elasticum: genetics, clinical manifestations and therapeutic approaches. Surv Ophthalmol 54(2):272–285PubMed

47.

Goodman G, von Sallmann L, Holland MG (1957) Ocular manifestations of sickle-cell disease. AMA Arch Ophthalmol 58(5):655–682PubMed

48.

Aessopos A, Farmakis D, Loukopoulos D (2002) Elastic tissue abnormalities resembling pseudoxanthoma elasticum in β-thalassemia and the sickling syndromes. Blood 99(1):30–35PubMed

49.

Hamlin N, Beck K, Bacchelli B, Cianciulli P, Pasquali-Ronchetti I, Le Saux O (2003) Acquired Pseudoxanthoma elasticum-like syndrome in β-thalassaemia patients. Br J Haematol 122(5):852–854PubMed

50.

Bunda S, Kaviani N, Hinek A (2005) Fluctuations of intracellular iron modulate elastin production. J Biol Chem 280(3):2341–2351PubMed

51.

Martin L, Douet V, VanWart CM, Heller MB, Le Saux O (2011) A mouse model of β-thalassemia shows a liver-specific down-regulation of ABCC6 expression. Am J Pathol 178(2):774–783PubMedPubMedCentral

52.

Jiang Q, Matsuzaki Y, Li K, Uitto J (2006) Transcriptional regulation and characterization of the promoter region of the human ABCC6 gene. J Investig Dermatol 126(2):325–335PubMed

53.

Georgalas I, Papaconstantinou D, Koutsandrea C et al (2009) Angioid streaks, clinical course, complications, and current therapeutic management. Ther Clin Risk Manag 5:81PubMedPubMedCentral

54.

Aessopos A, Stamatelos G, Savvides P et al (1989) Angioid streaks in homozygous β-thalassemia. Am J Ophthalmol 108(4):356–359PubMed

55.

Gibson J, Chaudhuri P, Rosenthal A (1983) Angioid streaks in a case of beta thalassaemia major. Br J Ophthalmol 67(1):29PubMedPubMedCentral

56.

Kinsella FP, Mooney DJ (1988) Angioid streaks in beta thalassaemia minor. Br J Ophthalmol 72(4):303–304PubMedPubMedCentral

57.

Aessopos A, Floudas CS, Kati M et al (2008) Loss of vision associated with angioid streaks in β-thalassemia intermedia. Int J Hematol 87(1):35–38PubMed

58.

Issa PC, Finger RP, Götting C, Hendig D, Holz FG, Scholl HP (2010) Centrifugal fundus abnormalities in pseudoxanthoma elasticum. Ophthalmology 117(7):1406–1414

59.

Incorvaia C, Parmeggiani F, Costagliola C, Perri P, D’Angelo S, Sebastiani A (2003) Quantitative evaluation of the retinal venous tortuosity in chronic anaemic patients affected by β-thalassaemia major. Eye 17(3):324PubMed

60.

Sorcinelli R, Sitzia A, Figus A, Lai M (1990) Ocular findings in beta-thalassemia. Metab Pediatr Syst Ophthalmol (New York, NY: 1985) 13(1):23–25

61.

Moiseyev G, Chen Y, Takahashi Y, Wu BX, Ma J-X (2005) RPE65 is the isomerohydrolase in the retinoid visual cycle. Proc Natl Acad Sci 102(35):12413–12418PubMed

62.

Błasiak J, Skłodowska A, Ulińska M, Szaflik J (2009) Iron and age-related macular degeneration. Klin Oczna 111(4–6):174–177PubMed

63.

Mehta S, Dunaief JL (2012) The role of iron in retinal diseases. In: Studies on retinal and choroidal disorders. Humana Press, pp 259–275

64.

Davies S, Hungerford J, Arden G, Marcus R, Miller M, Huehns E (1983) Ocular toxicity of high-dose intravenous desferrioxamine. Lancet 322(8343):181–184

65.

Olivieri NF, Buncic JR, Chew E et al (1986) Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 314(14):869–873PubMed

66.

Baath JS, Lam WC, Kirby M, Chun A (2008) Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population. Retina (Philadelphia, Pa) 28:894–899

67.

Haimovici R, D’Amico DJ, Gragoudas ES, Sokol S (2002) The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology 109:164–171PubMed

68.

Wu C-H, Yang C-P, Lai C-C, Wu W-C, Chen Y-H (2014) Deferoxamine retinopathy: spectral domain-optical coherence tomography findings. BMC Ophthalmol 14(1):88PubMedPubMedCentral

69.

Gelman R, Kiss S, Tsang SH (2014) Multimodal imaging in a case of deferoxamine induced maculopathy. Retin Cases Brief Rep 8(4):306PubMedPubMedCentral

70.

Van Bol L, Alami A, Benghiat FS, Rasquin F (2014) Spectral domain optical coherence tomography findings in early deferoxamine maculopathy: report of two cases. Retin Cases Brief Rep 8(2):97–102PubMed

71.

Eleftheriadou M, Theodossiadis P, Rouvas A, Alonistiotis D, Theodossiadis G (2012) New optical coherence tomography fundus findings in a case of beta-thalassemia. Clin Ophthalmol (Auckland, NZ) 6:2119

72.

Simon S, Athanasiov PA, Jain R, Raymond G, Gilhotra JS (2012) Desferrioxamine-related ocular toxicity: a case report. Indian J Ophthalmol 60(4):315PubMedPubMedCentral

73.

Viola F, Barteselli G, Dell’Arti L et al (2012) Abnormal fundus autofluorescence results of patients in long-term treatment with deferoxamine. Ophthalmology 119(8):1693–1700PubMed

74.

Arora A, Wren S, Gregory Evans K (2004) Desferrioxamine related maculopathy: a case report. Am J Hematol 76(4):386–388PubMed

75.

Meerpohl JJ, Antes G, Rücker G et al (2012) Deferasirox for managing iron overload in people with thalassaemia. Cochrane Database Syst Rev (2)

76.

Galanello R (2007) Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. Ther Clin Risk Manag 3(5):795PubMedPubMedCentral

77.

Song D, Zhao L, Li Y et al (2014) The oral iron chelator deferiprone protects against systemic iron overload-induced retinal degeneration in hepcidin knockout mice. Invest Ophthalmol Vis Sci 55:4525–4532PubMedPubMedCentral

78.

Gartaganis SP, Zoumbos N, Koliopoulos JX, Mela EK (2000) Contrast sensitivity function in patients with beta-thalassemia major. Acta Ophthalmol Scand 78(5):512–515PubMed

79.

Ghazanfari A, Jafarzadehpour E, Heydarian S, Dailami KN, Karami H (2018) Comparison of contrast sensitivity in β-thalassemia patients treated by deferoxamine or deferasirox. J Optom 12:168–173PubMedPubMedCentral

80.

Spyridon G, Ioannis A, Nikolaos C et al (2010) Contrast sensitivity in patients with beta-thalassemia major and sickle cell disease under regular transfusions and treatment with desferrioxamine. Open Ophthalmol J 4:39

81.

Regan D, Neima D (1983) Low-contrast letter charts as a test of visual function. Ophthalmology 90(10):1192–1200PubMed

82.

Woods RL, Tregear SJ, Mitchell RA (1998) Screening for ophthalmic disease in older subjects using visual acuity and contrast sensitivity1. Ophthalmology 105(12):2318–2326PubMed

83.

Aminoff MJ (2012) Electrodiagnosis in clinical neurology. Elsevier, Amsterdam

84.

Arden G, Fojas M (1962) Electrophysiological abnormalities in pigmentary degenerations of the retina: assessment of value and basis. Arch Ophthalmol 68(3):369–389PubMed

85.

Scholl HP, Zrenner E (2000) Electrophysiology in the investigation of acquired retinal disorders. Surv Ophthalmol 45(1):29–47PubMed

86.

Dettoraki M, Kattamis A, Ladas I et al (2017) Electrophysiological assessment for early detection of retinal dysfunction in beta-thalassemia major patients. Graefe’s Arch Clin Exp Ophthalmol 255(7):1349–1358

87.

Economou M, Zafeiriou DI, Kontopoulos E et al (2006) Neurophysiologic and intellectual evaluation of beta-thalassemia patients. Brain Dev 28(1):14–18PubMed

88.

El-Shazly AA, Ebeid WM, Elkitkat RS, Deghedy MR (2017) Electroretinographic and visual-evoked potential changes in relation to chelation modality in children with thalassemia. Retina (Philadelphia, Pa) 37(6):1168–1175

89.

Gelmi C, Borgna-Pignatti C, Franchin S, Tacchini M, Trimarchi F (1988) Electroretinographic and visual-evoked potential abnormalities in patients with beta-thalassemia major. Ophthalmologica 196(1):29–34PubMed

90.

Wong V, Li A, Lee A (1993) Neurophysiologic study of β-thalassemia patients. J Child Neurol 8(4):330–335PubMed

91.

Zafeiriou DI, Kousi AA, Tsantali CT et al (1998) Neurophysiologic evaluation of long-term desferrioxamine therapy in beta-thalassemia patients. Pediatr Neurol 18(5):420–424PubMed

92.

De Virgiliis S, Congia M, Turco M et al (1988) Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia. Arch Dis Child 63(3):250–255PubMedPubMedCentral

93.

Marciani M, Cianciulli P, Stefani N et al (1991) Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function. Haematologica 76(2):131–134PubMed

94.

Aarabi B, Haghshenas M, Rakeii V (1998) Visual failure caused by suprasellar extramedullary hematopoiesis in beta thalassemia: case report. Neurosurgery 42(4):922–925PubMed

95.

Stamboulis E, Vlachou N, Drossou-Servou M et al (2004) Axonal sensorimotor neuropathy in patients with β-thalassaemia. J Neurol Neurosurg Psychiatry 75(10):1483–1486PubMedPubMedCentral

96.

Arden G, Wonke B, Kennedy C, Huehns E (1984) Ocular changes in patients undergoing long-term desferrioxamine treatment. Br J Ophthalmol 68(12):873–877PubMedPubMedCentral

97.

Jiang C, Hansen RM, Gee BE, Kurth SS, Fulton AB (1998) Rod and rod mediated function in patients with β-thalassemia major. Doc Ophthalmol 96(4):333–346PubMed

98.

Orton R, Sulh H (1985) Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy. Can J Ophthalmol 20(4):153–156PubMed

99.

Haimovici R, D’Amico DJ, Gragoudas ES, Sokol S, Group DRS (2002) The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology 109(1):164–171PubMed

100.

Ravelli M, Scaroni P, Mombelloni S et al (1990) Acute visual disorders in patients on regular dialysis given desferrioxamine as a test. Nephrol Dial Transpl 5(11):945–949

101.

Kertes PJ, Lee TK, Coupland SG (2004) The utility of multifocal electroretinography in monitoring drug toxicity: deferoxamine retinopathy. Can J Ophthalmol 39(6):656–661PubMed

102.

Rudd C, Evans PJ, Peeney A (1953) Ocular complications in thalassaemia minor. Br J Ophthalmol 37(6):353PubMedPubMedCentral

103.

Angelucci E, Brittenham GM, Mclaren CE et al (2000) Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 343(5):327–331PubMed

104.

Musallam KM, Cappellini MD, Taher AT (2013) Iron overload in β-thalassemia intermedia: an emerging concern. Curr Opin Hematol 20(3):187–192PubMed

105.

Musallam KM, Cappellini MD, Wood JC, Taher AT (2012) Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Rev 26:S16–S19PubMed

106.

Tavazzi D, Duca L, Graziadei G, Comino A, Fiorelli G, Cappellini MD (2001) Membrane-bound iron contributes to oxidative damage of β-thalassaemia intermedia erythrocytes. Br J Haematol 112(1):48–50PubMed

107.

Varano M, Scassa C (1998) Scanning laser ophthalmoscope microperimetry. Semin ophthalmol 13(4):203–209PubMed

108.

Issa PC, Finger RP, Holz FG, Scholl HP (2009) Multimodal imaging including spectral domain OCT and confocal near infrared reflectance for characterization of outer retinal pathology in pseudoxanthoma elasticum. Invest Ophthalmol Vis Sci 50(12):5913–5918

Titel: Ocular abnormalities in beta thalassemia patients: prevalence, impact, and management strategies
verfasst von: Samira Heydarian
Reza Jafari
Kiumars Nowroozpoor Dailami
Hassan Hashemi
Ebrahim Jafarzadehpour
Mohsen Heirani
Abbasali Yekta
Monireh Mahjoob
Mehdi Khabazkhoob
Publikationsdatum: 10.10.2019
Verlag: Springer Netherlands
Erschienen in: International Ophthalmology / Ausgabe 2/2020
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-019-01189-3

Neu im Fachgebiet Augenheilkunde

08.04.2024 | Therapieverfahren in der Augenheilkunde | CME

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Ocular abnormalities in beta thalassemia patients: prevalence, impact, and management strategies

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

Bestmögliche Wundheilung der Kornea dank optimaler pharmakologischer Therapie

Update Augenheilkunde

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Sagittal height differences of disposable soft contact lenses

Corneal topography and angle parameters after laser iridotomy combined with iridoplasty assessed by dual Scheimpflug analyzer

CDKN2A, CDK1, and CCNE1 overexpression in sebaceous gland carcinoma of eyelid

Retinopathy of prematurity occurrence and evaluation of screening policy in a large tertiary Greek cohort

Vertical rectus muscle union combined with lateral rectus plication for complete abducens nerve palsy

Features of the choriocapillaris on four different optical coherence tomography angiography devices

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

Bestmögliche Wundheilung der Kornea dank optimaler pharmakologischer Therapie

Update Augenheilkunde